Geneva, Switzerland and Boston, MA – October 31, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s...
MORRISVILLE, N.C.–(BUSINESS WIRE)– 15 patients have been randomized 83% initial response rate to qualify for randomization Pulmonary capillary wedge pressure (PCWP) was reduced , on average, by 8 mmHg during exercise following the initial levosimendan...
Studies Aim to Confirm Safety and Efficacy of Novel Bio-inspired Clot-dissolving Therapy CAMBRIDGE, Mass, USA October 30, 2019 / B3C newswire / — Thrombolytic Science, LLC (TSI) today announced progress with 10 patients enrolled in its prospective, randomized,...
– Voclosporin ophthalmic solution (VOS) AUDREY trial results anticipated in the second half of 2020 – VICTORIA, British Columbia–(BUSINESS WIRE)–Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical...
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 31, 2019 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced the publication of...
Pinteon Therapeutics today announced the launch of a Phase 1 trial of PNT001, a novel tau antibody that uniquely targets a toxic epitope known to drive neurodegenerative disease. Pinteon is funded by a $17 million Series A from Morningside Ventures and led by an...
Email
Text